Makes sense.
It's a bit hard to draw conclusions regarding PFS from the data they've given us but obviously they've got a bit more data than us and know it's positive. As someone else mentioned too - only 3 or 4 of the 14 were on the 400mg dose that was ultimately chosen for 2a.
Market still staying away from this one until capital sorted out. I'm still expecting a cap raise reasonably soon.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-13
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
